Real-world evaluation of ImmuCare-PRO patient-reported outcomes in melanoma patients treated with immune checkpoint inhibitors
The ImmuCare-PRO system correctly detected a third of moderate-to-severe IrAEs, and most of those had clinical impact such as skin toxicities, colitis, and rheumatological IrAEs. This enables earlier management and could avoid unnecessary emergency room visits.
Authors
- Maxime Bonjour (ORCID: https://orcid.org/0000-0003-2205-9655)
- Denis Maillet (ORCID: https://orcid.org/0000-0001-6883-2696)
- S. Dalle
- S. Milley
- Delphine Maucort‐Boulch (ORCID: https://orcid.org/0000-0003-0042-7787)
- C. Dolla
- Samy Belkaïd (ORCID: https://orcid.org/0000-0002-0350-1703)
- L. Thomas (ORCID: https://orcid.org/0000-0003-1995-2434)
- R. Saux
- A. Augros
- P.J. Souquet
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Lyon Sud (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100090
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hospices Civils de Lyon